Skip redundant pieces
KU Center for Technology Commercialization
Inventors

    Innovation Sphere

Researchers

  • Charlotte Vines
  • Tiffany McBurney
  • James Deng

Communicate

Details

Project TitleDevelopment of a Novel Adjuvant for Vaccine Administration
Track Code10KU012M
Websitehttp://kuic.dept.ku.edu/sites/default/files/Development_%20of_Novel_Adjuvant_for_Vaccine_Administration.pdf
Short Description

Development of a Novel Adjuvant for Vaccine Administration The invention proposes to develop CCR7 antagonists as novel vaccine adjuvants. 

AbstractNone
 
TagsVaccine Administration, Vaccine Adjuvants
 
Posted DateSep 3, 2013 12:44 PM

Researcher

Name
Charlotte Vines
Tiffany McBurney
James Deng

Manager

Name
Matthew Koenig

Benefits

  • Novel adjuvant that is both safe and effective in humans
  • Improved response to immunogenic stimulations
  • Modulation of T cells and therefore regulation of immune response

Applications

  • Vaccine development
  • Immunization of people and animals against immunogens that currently induce a weak immune response

Overview

At present, few adjuvants are known to safely enhance a human patient’s immune response to vaccinations. In fact, only alum is licensed by the FDA for use in human vaccines. Thus, the development of additional adjuvants that are both safe and effective would be extremely valuable in advancing human health.

Current literature suggests that mice lacking the CCR7 receptor or its ligands have enhanced immune responses. As such, temporary suppression of CCR7 and its ligands in humans could enhance a patient’s response to immunogenic stimulations. The use of CCR7 antagonists as vaccine adjuvants would have particularly important applications in the field of vaccine development.

Why it is better

This invention involves a novel adjuvant that is both safe and effective for use in human, farm, and domestic animals. The invention would be used during routine immunizations in order to boost the normal immune response in the targeted host. This is especially relevant to the development of vaccination protocols, as the novel adjuvant could ultimately provide for the immunization of people and animals against immunogens that currently induce weak immune responses.

    

Patent Pending.

Contact Information

Matt Koenig, J.D.

KU Center for Technology Commercialization (785) 864-1774 mekoenig@ku.edu



Page last modified: Thursday December 04, 2008  •  Valid XHTML  •  Copyright © 2008 by the University of Kansas